Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
Cantor Fitzgerald
McKesson
UBS
Deloitte
Covington
Cipla
Julphar

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,001,876

« Back to Dashboard

Which drugs does patent 6,001,876 protect, and when does it expire?

Patent 6,001,876 protects LYRICA and is included in two NDAs.

This patent has twenty-nine patent family members in twenty-three countries.
Summary for Patent: 6,001,876
Title: Isobutylgaba and its derivatives for the treatment of pain
Abstract:The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.
Inventor(s): Singh; Lakhbir (Cambridgeshire, GB)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:09/043,358
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,001,876

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-001 Dec 30, 2004 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF FIBROMYALGIA ➤ Try a Free Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-001 Dec 30, 2004 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF PAIN ➤ Try a Free Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-002 Dec 30, 2004 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF FIBROMYALGIA ➤ Try a Free Trial
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-002 Dec 30, 2004 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF PAIN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,001,876

PCT Information
PCT FiledJuly 16, 1997PCT Application Number:PCT/US97/12390
PCT Publication Date:January 29, 1998PCT Publication Number: WO98/03167

Non-Orange Book US Patents Family Members for Patent 6,001,876

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE41920 Isobutylgaba and its derivatives for the treatment of pain ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,001,876

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 934061 ➤ Try a Free Trial
Poland 189872 ➤ Try a Free Trial
Poland 331325 ➤ Try a Free Trial
New Zealand 332762 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Chubb
Cerilliant
Healthtrust
Cantor Fitzgerald
AstraZeneca
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.